Search results for: 'ai infrastructure development access a9aa'

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides actionable insights across new developments in prebiotics, immunology, oncology, cell and gene therapies, antibody therapies, and precision medicine approaches. The TOE also encompasses technology advances across the use of AI and ML in drug discovery a...

The global biopharma patient access market is undergoing a structural shift as specialty medicines make downstream commercialization more complex and strategically important. Patient access is no longer limited to reimbursement support or hub services; it is becoming a commercialization control layer spanning authorization, affordability, therapy i...

The discovery of new drug targets for diseases with unmet medical needs has long been hindered by the complexity of processing and interpreting massive volumes of biological data. The increasing volume and veracity of clinical and research data compels the use of enabling tools and technologies, such as cloud computing, AI, machine learning, natura...

The impact of the digital revolution continues to disrupt the healthcare industry. This includes evolving digital technological capabilities, new business models and marketing approaches, the healthcare consumerism trend, the changing regulatory environment, and competitive threats from new market entrants, such as digital-native companies—particul...

Microbiome research is on the rise following technological advancements and significant cost reductions in microbiome analysis. Research has unlocked the potential of microbiome in medical use cases, yielding tremendous insights on its nature, interactions, and impact within a host and in an external environment. Advanced studies on the role of mic...

01 Feb 2022  |  Global  |  Frost Radar

Frost Radar™: Global Enterprise Health Cloud Infrastructure and Platform Services, 2021

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

The COVID-19 pandemic has revealed that many healthcare organizations have neither the agility and business continuity programs nor the technologies needed to support them during a crisis. Consequently, some have been forced to act on cloud and digital transformation strategies they had been delaying. The cloud has been critical in helping healthca...

Artificial intelligence is becoming increasingly relevant to antibody discovery and immunotherapy development, supporting target identification, de novo antibody design, antibody engineering, clinical intelligence, and bioprocessing. Advances in generative AI, protein language models, diffusion models, and structure-based models are expanding the u...

Conversational AI solutions are designed to enhance communication and coordination among healthcare stakeholders. These voice and text applications automate human information gathering and communications and represent a growing opportunity for healthcare organizations to improve clinician efficiency, operational and administrative efficiency, healt...

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...